{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T01:26:16Z","timestamp":1774574776801,"version":"3.50.1"},"reference-count":23,"publisher":"Cambridge University Press (CUP)","issue":"5-6","license":[{"start":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T00:00:00Z","timestamp":1586995200000},"content-version":"unspecified","delay-in-days":5372,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur. psychiatr."],"published-print":{"date-parts":[[2005,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec id=\"S0924933800241369_sec0030\" sec-type=\"other\"><jats:title>Objective<\/jats:title><jats:p>Antipsychotic medications may reduce hostile and aggressive behavior in schizophrenia. This study compared the effectiveness of antipsychotics in the treatment of aggression.<\/jats:p><\/jats:sec><jats:sec id=\"S0924933800241369_sec0032\" sec-type=\"methods\"><jats:title>Method<\/jats:title><jats:p>The Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study compares the effectiveness of antipsychotic treatments in practice setting. Schizophrenia outpatients who initiated or changed to a new antipsychotic are followed in this non-interventional, prospective observational study for up to 3\u00a0years, with 6-months data now available on the entire cohort (<jats:italic>N<\/jats:italic> = 7655). The presence or absence of verbal or physical hostility\/aggression was assessed retrospectively for the period of 6\u00a0months before enrollment, and prospectively in the period of 6\u00a0months after enrollment (the study treatment period). At baseline, patients in five monotherapy treatment groups (combined <jats:italic>N<\/jats:italic> = 3135) were prescribed one of the treatments: clozapine, olanzapine, quetiapine, risperidone, or haloperidol, and had complete data.<\/jats:p><\/jats:sec><jats:sec id=\"S0924933800241369_sec0033\" sec-type=\"results\"><jats:title>Results<\/jats:title><jats:p>Hostile\/aggressive behavior was reduced during the treatment period. Olanzapine and risperidone were significantly superior to haloperidol and to clozapine in this respect. These results remained essentially unchanged when adjusting for baseline imbalances in age, gender, age of onset, and substance abuse.<\/jats:p><\/jats:sec><jats:sec id=\"S0924933800241369_sec0034\" sec-type=\"conclusions\"><jats:title>Conclusions<\/jats:title><jats:p>As monotherapy, both olanzapine and risperidone were superior to haloperidol and clozapine in reducing aggression. The relative lack of effectiveness of clozapine may be specific to this study population.<\/jats:p><\/jats:sec>","DOI":"10.1016\/j.eurpsy.2005.01.009","type":"journal-article","created":{"date-parts":[[2005,8,4]],"date-time":"2005-08-04T19:57:38Z","timestamp":1123185458000},"page":"403-408","source":"Crossref","is-referenced-by-count":39,"title":["Effectiveness of clozapine, olanzapine, quetiapine, risperidone, and haloperidol monotherapy in reducing hostile and aggressive behavior in outpatients treated for schizophrenia: a prospective naturalistic study (IC-SOHO)"],"prefix":"10.1017","volume":"20","author":[{"given":"Istvan","family":"Bitter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pal","family":"Czobor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Dossenbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Volavka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2020,4,16]]},"reference":[{"key":"S0924933800241369_bib0001","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-200501000-00004"},{"key":"S0924933800241369_bib0023","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1176\/ps.46.4.386","article-title":"18-month outcome of clozapine treatment for 100 patients in a state psychiatric hospital","volume":"46","author":"Wilson","year":"1995","journal-title":"Psychiatr. Serv."},{"key":"S0924933800241369_bib0021","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.171.1.9"},{"key":"S0924933800241369_bib0002","first-page":"607","article-title":"Violence and schizophrenia: clozapine as a specific antiaggressive agent","volume":"23","author":"Buckley","year":"1995","journal-title":"Bull. Am. Acad. Psychiatry Law"},{"key":"S0924933800241369_bib0010","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0447.107.s416.5.x"},{"key":"S0924933800241369_bib0003","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(03)80094-2"},{"key":"S0924933800241369_bib0009","volume-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy","year":"1976"},{"key":"S0924933800241369_bib0019","first-page":"49","article-title":"Observational study of schizophrenia outpatients in Central and Eastern Europe: 3- and 6-month efficacy and safety results","volume":"32","author":"Treuer","year":"2004","journal-title":"Socialna Psihijatria"},{"key":"S0924933800241369_bib0014","first-page":"297","article-title":"The impact of clozapine on 25 forensic patients","volume":"20","author":"Maier","year":"1992","journal-title":"Bull. Am. Acad. Psychiatry Law"},{"key":"S0924933800241369_bib0015","first-page":"395","article-title":"Restraint, seclusion, and clozapine","volume":"53","author":"Mallya","year":"1992","journal-title":"J. Clin. Psychiatry"},{"key":"S0924933800241369_bib0017","first-page":"245","article-title":"Diminished suicidal and aggressive behavior, high plasma norepinephrine levels, and serum triglyceride levels in chronic neuroleptic-resistant schizophrenic patients maintained on clozapine","volume":"21","author":"Spivak","year":"1998","journal-title":"Clin. Neuropharmacol."},{"key":"S0924933800241369_bib0004","first-page":"269","article-title":"Effects of clozapine on use of seclusion and restraint at a state hospital","volume":"45","author":"Chiles","year":"1994","journal-title":"Hosp. Community Psychiatry"},{"key":"S0924933800241369_bib0005","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.52.11.1510"},{"key":"S0924933800241369_bib0006","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199508000-00002"},{"key":"S0924933800241369_bib0007","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v65n0305"},{"key":"S0924933800241369_bib0008","first-page":"271","article-title":"Patient response to clozapine in a forensic psychiatric hospital","volume":"45","author":"Ebrahim","year":"1994","journal-title":"Hosp. Community Psychiatry"},{"key":"S0924933800241369_bib0011","first-page":"17","article-title":"Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia","volume":"62","author":"Kinon","year":"2001","journal-title":"J. Clin. Psychiatry"},{"key":"S0924933800241369_bib0012","first-page":"163","article-title":"The Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study: Baseline clinical and functional characteristics and antipsychotic use of patterns in the Central and Eastern Europe (CEE) region","volume":"15","author":"Korb","year":"2003","journal-title":"Psychiatria Danubina"},{"key":"S0924933800241369_bib0013","first-page":"27","article-title":"The intercontinental schizophrenia outpatient health outcomes (ic-soho) study: baseline clinical and functional characteristics and antipsychotic use patterns in the North Africa and Middle Eastern (amea) region","volume":"7","author":"Korb","year":"2004","journal-title":"South African Psychiatry Review"},{"key":"S0924933800241369_bib0016","first-page":"219","article-title":"The effects of clozapine on severely aggressive psychiatric inpatients in a state hospital","volume":"54","author":"Ratey","year":"1993","journal-title":"J. Clin. Psychiatry"},{"key":"S0924933800241369_bib0020","volume-title":"Neurobiology of Violence","author":"Volavka","year":"2002"},{"key":"S0924933800241369_bib0022","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199308000-00012"},{"key":"S0924933800241369_bib0018","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v65n1212"}],"container-title":["European Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924933805001045?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924933805001045?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0924933800241369","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,20]],"date-time":"2020-04-20T02:20:54Z","timestamp":1587349254000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0924933800241369\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8]]},"references-count":23,"journal-issue":{"issue":"5-6","published-print":{"date-parts":[[2005,8]]}},"alternative-id":["S0924933800241369"],"URL":"https:\/\/doi.org\/10.1016\/j.eurpsy.2005.01.009","relation":{},"ISSN":["0924-9338","1778-3585"],"issn-type":[{"value":"0924-9338","type":"print"},{"value":"1778-3585","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,8]]}}}